Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Sangamo Therapeutics, Inc. is a biotechnology company focused on developing genomic therapies for rare diseases and serious conditions, leveraging its proprietary gene-editing technology. The company operates primarily in the United States, with a pipeline that includes therapies for hemophilia and neurodegenerative diseases, setting it apart through its innovative approach to gene therapy.
Sangamo generates revenue primarily through collaboration agreements with larger pharmaceutical companies, which provide upfront payments and milestone payments tied to the development of therapies. The company’s competitive advantage lies in its proprietary zinc finger protein technology, which allows for precise gene editing, potentially leading to better therapeutic outcomes compared to traditional methods.
Progress in clinical trials for gene therapies, particularly for hemophilia and neurodegenerative diseases
Partnership announcements or collaborations with larger pharmaceutical companies
Regulatory approvals or setbacks from the FDA
Market sentiment towards gene editing technologies
Regulatory changes affecting gene therapy approvals
Technological disruption from competing gene editing technologies
Emergence of new gene editing technologies from competitors like CRISPR Therapeutics
Potential for larger pharmaceutical companies to develop in-house capabilities
High cash burn rate leading to liquidity concerns
Negative gross and operating margins indicating unsustainable business model without revenue growth
low - The demand for biotechnology products is less sensitive to economic cycles, as they often address critical health needs.
Interest rates affect Sangamo's cost of capital and valuation multiples, as higher rates could increase the discount rate applied to future cash flows, impacting stock valuation.
minimal - The company has a negative debt/equity ratio, indicating it is not reliant on debt financing.
growth - Investors are likely attracted to the potential for high returns from successful gene therapies.
high - The stock has experienced significant volatility due to clinical trial outcomes and market sentiment.
